Ad
related to: fda orphan drug
Search results
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 7 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day ...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 6 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
NBC 17 Raleigh· 6 days agoKS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks via Yahoo Finance· 4 days agoIt enables early interactions between the FDA and sponsors to facilitate accelerated approval and...
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks via Yahoo Finance· 5 days agoNomlabofusp has received Rare Pediatric Disease designation, Fast Track designation and Orphan Drug...
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Clinical Trials Arena via Yahoo Finance· 3 days agoVerastem stated the dose cohort was cleared after additional patients were evaluated. Avutometinib...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 5 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX...
FOX 23 News Albany· 6 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
ORPHAN Cures | Pacific Sun
Pacific Sun· 5 days agoAdding insult to illness, an element of 2022’s Inflation Reduction Act (IRA) discourages research into treatments for rare conditions. The good news is that Congress can undo this unintended ...
Biogen is buying up an immune drug developer for $1.8 billion
Quartz· 5 days agoBiotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human...